Cybersecurity incident prompts Henry Schein to take systems offline, disrupting operations
The incident affected a portion of the medical supply company’s manufacturing and distribution businesses.
Uncategorized
BD recycles 40,000 pounds of medical waste in circular economy pilot project
The collaborators assessed the feasibility of recycling medical waste such as plastic syringes.
BD recycles 40,000 pounds of medical waste in circular economy pilot project Read More »
Traverse Biotech has been awarded a Phase I SBIR grant from the National Cancer Institute to develop targeted immunotherapy for selected solid tumors
Traverse Biotech, Inc announced today that the National Cancer Institute (NCI) of the National Institutes of Health has awarded them a Small Business Innovation Research (SBIR) Phase 1 Grant to fund the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC).
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023.
Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.
Explorando los fenómenos paranormales: ¿Realidad o ilusión?
A lo largo de la historia, los fenómenos paranormales han intrigado a la humanidad. Desde la telequinesis y la clarividencia hasta la percepción extrasensorial (PES), estos conceptos desafían nuestra comprensión convencional del mundo. Adentrémonos en el mundo de l …
Explorando los fenómenos paranormales: ¿Realidad o ilusión? Read More »
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced the U.S. Food and Drug Administration granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease.
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
Sensorion is pleased to announce its participation, in-person, in the European Society of Gene & Cell Therapy conference, taking place on October 24-27, 2023, in Brussels, Belgium.
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference Read More »
Semarion Announces Early Adopter Programme for SemaCyte Microcarrier Platform
Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform.
Semarion Announces Early Adopter Programme for SemaCyte Microcarrier Platform Read More »
Telix reports fourth consecutive quarter of positive operating cash flow
Telix Pharmaceuticals Limited issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023.
Telix reports fourth consecutive quarter of positive operating cash flow Read More »